Prescient’s PTX-100 granted FDA’s Orphan Drug Designation for all T-cell lymphomas
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of...
The granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity of...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has secured an orphan drug designation from the US...
Clinical-stage oncology entity Prescient Therapeutics (ASX: PTX) -- focused on the development of novel and...
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage...
Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy...
COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by...
Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for...
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to...
Stockhead’s Year in Review video series is a yearly wrap up address from company leaders...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.